1882-72-0

Usage

Uses

Used in Fragrance and Flavor Industry:
Methyl 2-amino-5-hydroxybenzoate is used as a fragrance and flavoring agent for its sweet, fruity odor, adding a pleasant scent and taste to various consumer products such as perfumes, soaps, and cosmetics.
Used in Pharmaceutical Industry:
Methyl 2-amino-5-hydroxybenzoate is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Organic Chemical Reactions:
As an intermediate in organic chemical reactions, methyl 2-amino-5-hydroxybenzoate plays a crucial role in the production of various chemical compounds and materials.
Used in Antioxidant and Antimicrobial Applications:
Methyl 2-amino-5-hydroxybenzoate has been studied for its potential antioxidant and antimicrobial properties, indicating its possible use in applications that require preservation and protection against harmful microorganisms.

InChI:InChI=1/C8H9NO3/c1-12-8(11)6-4-5(10)2-3-7(6)9/h2-4,10H,9H2,1H3

Upstream product

• 67-56-1 methanol 
• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 606-27-9 methyl 2-nitrobenzoate 
• 59216-77-2 methyl 5-hydroxy-2-nitro-benzoate 
• 186581-53-3 diazomethane 
• 78183-21-8 avenalumin I diacetate 
• 1882-75-3 6-acetoxy-2-methyl-4H-3,1-benzoxazin-4-one 
• 78164-38-2 Avenalumin 1 

Downstream Products

• 179756-40-2 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]anthranilate 
• 773071-76-4 methyl 2-amino-5-(2-methoxyethoxy)benzoate 
• 2475-80-1 methyl 2-amino-5-methoxybenzoate 
• 1627498-12-7 C₁₇H₁₈N₂O₄ 
• 233281-67-9 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[(7-cyano-2-naphthyl)methyl]anthranilate 
• 540765-43-3 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-{[(3-cyanophenyl)(methyl)carbamoyl]methyl}anthranilate 
• 233282-02-5 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-{[(3-cyanophenyl)carbamoyl]methyl}anthranilate 
• 233281-63-5 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[(E)-3-cyanocinnamyl]anthranilate 
• 540765-38-6 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[3-(3-cyanophenyl)propyl]anthranilate 
• 540765-40-0 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[2-(3-cyanophenoxy)ethyl]anthranilate 
• 233282-00-3 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-{[(3-cyanophenyl)carbamoyl]methyl}-N-(2,2,2-trifluoroacetyl)anthranilate 
• 233281-98-6 methyl N-benzyloxycarbonylmethyl-5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(2,2,2-trifluoroacetyl)anthranilate 
• 540765-37-5 7-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-1-[(E)-3-cyanocinnamyl]-1H-1,4-benzodiazepine-2,5(3H,4H)-dione 
• 179756-41-3 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-[(7-cyano-2-naphthyl)methyl]anthranilate 

Relevant academic research and scientific papers

Polyvalent Catalysts Operating on Polyvalent Substrates: A Model for Surface-Controlled Reactivity

Unusually fast rates of nucleophilic catalysis of hydrazone ligation were observed when polyvalent anthranilic acid catalysts operating on polyvalent aldehyde substrates were used with PAMAM dendrimers as the common platform. When presented in this way, t

COMPUTATIONAL INVESTIGATIONS, HIRSHFELD SURFACE ANALYSIS, INTERACTION ENERGY CALCULATIONS, AND ENERGY FRAMEWORK CRYSTAL STRUCTURE OF METHYL 2-AMINO-5-HYDROXYBENZOATE

Abstract: The title compound with the molecular formula C8H9NO3 is synthesized by refluxing 2-amino-5-hydroxybenzoic acid in methanol. The molecular structure of the compound is determined by single crystal X-ray diffracti

Distinct urinary metabolite profiles of two pharmacologically active N-methylanthranilates: Three approaches to xenobiotic metabolite identification

Two volatile alkaloids, isopropyl N-methylanthranilate (IMA) and methyl N-methylanthranilate (MMA), present in the human diet and cosmetic products, were recently demonstrated to possess important pharmacological activities. While MMA is considered to be phototoxic, there is scarce data on the toxicity of IMA. Herein, we analyzed urinary metabolites of IMA and MMA in rats (200 mg kg?1, i.p., 7 days) by combining three different approaches: 1) preparative chromatography, 2) synthesis, and 3) SPR. The preparative approach, Sephadex LH-20 chromatography of the extract of urine samples of IMA treated animals, in conjunction with NMR, enabled the identification of 16 different anthranilate derivatives, among which products of aromatic core hydroxylation (isopropyl 5-hydroxy-N-methylanthranilate, isopropyl 5-hydroxyantranilate, isopropyl 3-hydroxyantranilate) were the major ones. The first application of the synthetic/combinatorial approach led to a successful identification of MMA metabolites, where 2-(methylamino)benzamide and N-methylanthranilic acid were the principal ones, among 14 others. Generally, MMA and IMA undergo analogous biotransformation pathways; however, MMA predominantly underwent chemical conversions of the ester group, i.e. transformation into derivatives of anthranilamide and anthranilic acid, while the major metabolic pathway of IMA was hydroxylation of the aromatic core. Additionally, pathohistological examinations revealed no signs of liver toxicity, or other signs of toxicity.

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

Compounds for use in inhibiting HIV capsid assembly

The present invention relates to a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, the compound comprising the core structure wherein E is CR7or S, and wherein f is 0 or 1, and wherein in case E is S, f is 0, and wherein the core structure is at least substituted in 2 and 4 position, and wherein the residue R6 and R7, are, independently of each other, selected from the group consisting of -H, -D, -alkyl, alkoxy, alkenyl, alkynyl, halides, -NO2, - OH, - NH2, -NHR4#, -CN, -S(O)R4#, -SO2R4#, -P(O)R4#R5#, -P(O)(OR4#)R5#, - P(O)(OR4#)(OR5#), -C(O)NR4#R5#, -C(O)SR4#, -C(O)R4#, -C(O)O-R4#, alkoxy and glycol chains; and wherein R6 may optionally form a cyclic residue, with a further substituent present 5 or 6 position, and wherein R4# and R5# are, independently of each other, selected from the group consisting of -H, -alkyl, -alkenyl, - heterocycloalkyl, aryl and heteroaryl.

COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY

The present invention relates to a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, the compound comprising the core structure wherein E is CR7or S, and wherein f is 0 or 1, and wherein in case E is S, f is 0, and wherein the core structure is at least substituted in 2 and 4 position, and wherein the residue R6 and R7, are, independently of each other, selected from the group consisting of -H, -D, -alkyl, alkoxy, alkenyl, alkynyl, halides, -NO2, - OH, -NH2, -NHR4#, -CN, - S(O)R4#, -SO2R4#, -P(O)R4#R5#, -P(O)(OR4#)R5#, -P(O)(OR4#)(OR5#), -C(O)NR4#R5#, - C(O)SR4#, -C(O)R4#, -C(O)O-R4#, alkoxy and glycol chains; and wherein R6 may optionally form a cyclic residue, with a further substituent present 5 or 6 position, and wherein R4# and R5# are, independently of each other, selected from the group consisting of -H, -alkyl, -alkenyl, -heterocyclo alkyl, aryl and heteroaryl.

Supramolecular chemistry with ureido-benzoic acids

The controlled self-assembly of multiple molecules into predefined architectures requires highly directional and controllable non-covalent interactions with a high association constant. Here, we introduce the self-complementary ureido-benzoic acid (UBA) q

Discovery of novel bacterial RNA polymerase inhibitors: Pharmacophore-based virtual screening and hit optimization

The bacterial RNA polymerase (RNAP) is a validated target for broad spectrum antibiotics. However, the efficiency of drugs is reduced by resistance. To discover novel RNAP inhibitors, a pharmacophore based on the alignment of described inhibitors was used for virtual screening. In an optimization process of hit compounds, novel derivatives with improved in vitro potency were discovered. Investigations concerning the molecular mechanism of RNAP inhibition reveal that they prevent the protein-protein interaction (PPI) between σ70 and the RNAP core enzyme. Besides of reducing RNA formation, the inhibitors were shown to interfere with bacterial lipid biosynthesis. The compounds were active against Gram-positive pathogens and revealed significantly lower resistance frequencies compared to clinically used rifampicin.

HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM

The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the HIV gp41 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN36 (SEQ ID NO:1); a second helical polypeptide consisting essentially of the sequence of C34 (SEQ ID NO: 2) wherein said IQN36 is labeled with a light emitting fluorophore and said C34 is labeled with an ultra-violet excitable fluorophore.

VIRAL POLYMERASE INHIBITORS

The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical